Back to today’s briefing

Story perspectives

Psilocybin Shows Promise in Alleviating Cancer-Related Depression

6/19/2025

38 9

Summary

Story summary

A groundbreaking clinical trial in CANCER reveals that a single 25-mg dose of psilocybin can dramatically alleviate depression and anxiety in cancer patients battling major depressive disorder. Remarkably, two years later, over half of the participants reported feeling better. Ongoing studies are set to explore the potential of multiple doses, paving the way for innovative treatments in cancer-related depression.

1 of 1

Story summary

A groundbreaking clinical trial in CANCER reveals that a single 25-mg dose of psilocybin can dramatically alleviate depression and anxiety in cancer patients battling major depressive disorder. Remarkably, two years later, over half of the participants reported feeling better. Ongoing studies are set to explore the potential of multiple doses, paving the way for innovative treatments in cancer-related depression.